A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of Oral ELND005 (scyllo-Inositol) in Young Adults with Down Syndrome Without Dementia

Overview

Journal J Alzheimers Dis

Publisher Sage Publications

Specialties Geriatrics
Neurology

Date 2017 Apr 29

PMID 28453471

Citations 19

Authors

Michael S Rafii

Brian G Skotko

Mary Ellen McDonough

Margaret Pulsifer

Casey Evans

Eric Doran

Gabriela Muranevici

Patrick Kesslak

Susan Abushakra

Ira T Lott

Affiliations

Soon will be listed here.

Abstract

Background: ELND005 (scyllo-Inositol; cyclohexane-1,2,3,4,5,6-hexol) has been evaluated as a potential disease-modifying treatment for Alzheimer's disease (AD). Individuals with Down syndrome (DS) have an increased risk for developing AD dementia.

Objective: To evaluate the safety and tolerability of ELND005 and to determine its pharmacokinetics (PK) and relationship between PK parameters, safety outcome measures, and exploratory efficacy outcome measures in young adults with DS without dementia.

Methods: This was a prospective, randomized, double-blind, placebo-controlled, parallel-group, three-arm, multicenter Phase II study of the safety and pharmacokinetics of ELND005 administered orally for 4 weeks (ClinicalTrials.gov NCT01791725). Participants who met study eligibility criteria were randomly assigned in a 2 : 1:1 ratio to receive ELND005 at either 250 mg twice daily (BID) or 250 mg once daily (QD) or matching placebo for 4 weeks.

Results: There were no apparent treatment group-related trends on cognitive or behavioral measures and there were no SAEs and no deaths in the study. Overall, mean changes from baseline in clinical laboratory parameters, vital sign measurements, electrocardiogram results, and other physical findings were unremarkable. ELND005 accumulation averaged approximately 2-fold with QD dosing, and 3- to 4-fold with BID dosing.

Conclusion: Overall, treatment of adults with DS with ELND005 at both doses was well tolerated, achieved measurable blood levels and demonstrated no safety findings. Further studies will be needed to test efficacy.

Citing Articles

Drug delivery strategies with lipid-based nanoparticles for Alzheimer's disease treatment.

Jang Y, Kang S, Park H, Lee D, Kim J, Kim J J Nanobiotechnology. 2025; 23(1):99.

PMID: 39930497 PMC: 11809104. DOI: 10.1186/s12951-025-03109-3.

Blockade of brain alkaline phosphatase efficiently reduces amyloid-β plaque burden and associated cognitive impairment.

Soria-Tobar L, Roman-Valero L, Sebastian-Serrano A, Aivar P, Alvarez-Castelao B, Diaz-Hernandez M Alzheimers Res Ther. 2024; 16(1):233.

PMID: 39438925 PMC: 11494749. DOI: 10.1186/s13195-024-01600-x.

"Down Syndrome is Not a Curse": parent Perspectives on the Medicalization of Down Syndrome.

Riggan K, Michie M, Allyse M AJOB Empir Bioeth. 2024; 16(1):10-21.

PMID: 39110899 PMC: 11785502. DOI: 10.1080/23294515.2024.2388533.

Cyclitols: From Basic Understanding to Their Association with Neurodegeneration.

Derkaczew M, Martyniuk P, Osowski A, Wojtkiewicz J Nutrients. 2023; 15(9).

PMID: 37432155 PMC: 10180955. DOI: 10.3390/nu15092029.

Detection and treatment of Alzheimer's disease in its preclinical stage.

Rafii M, Aisen P Nat Aging. 2023; 3(5):520-531.

PMID: 37202518 PMC: 11110912. DOI: 10.1038/s43587-023-00410-4.

References

Shonk T, Ross B . Role of increased cerebral myo-inositol in the dementia of Down syndrome. Magn Reson Med. 1995; 33(6):858-61. DOI: 10.1002/mrm.1910330619. View

Liang E, Garzone P, Cedarbaum J, Koller M, Tran T, Xu V . Pharmacokinetic Profile of Orally Administered Scyllo-Inositol (Elnd005) in Plasma, Cerebrospinal Fluid and Brain, and Corresponding Effect on Amyloid-Beta in Healthy Subjects. Clin Pharmacol Drug Dev. 2016; 2(2):186-94. DOI: 10.1002/cpdd.14. View

Lott I, Dierssen M . Cognitive deficits and associated neurological complications in individuals with Down's syndrome. Lancet Neurol. 2010; 9(6):623-33. DOI: 10.1016/S1474-4422(10)70112-5. View

Walsh D, Selkoe D . A beta oligomers - a decade of discovery. J Neurochem. 2007; 101(5):1172-84. DOI: 10.1111/j.1471-4159.2006.04426.x. View

Boada R, Hutaff-Lee C, Schrader A, Weitzenkamp D, Benke T, Goldson E . Antagonism of NMDA receptors as a potential treatment for Down syndrome: a pilot randomized controlled trial. Transl Psychiatry. 2012; 2:e141. PMC: 3410988. DOI: 10.1038/tp.2012.66. View

Cummings J, Mega M, Gray K, Carusi D, Gornbein J . The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994; 44(12):2308-14. DOI: 10.1212/wnl.44.12.2308. View

Townsend M, Cleary J, Mehta T, Hofmeister J, Lesne S, OHare E . Orally available compound prevents deficits in memory caused by the Alzheimer amyloid-beta oligomers. Ann Neurol. 2006; 60(6):668-76. DOI: 10.1002/ana.21051. View

Mohan M, Bennett C, Carpenter P . Rivastigmine for dementia in people with Down syndrome. Cochrane Database Syst Rev. 2009; (1):CD007658. PMC: 7197503. DOI: 10.1002/14651858.CD007658. View

Sperling R, Jack Jr C, Black S, Frosch M, Greenberg S, Hyman B . Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup. Alzheimers Dement. 2011; 7(4):367-85. PMC: 3693547. DOI: 10.1016/j.jalz.2011.05.2351. View

10.

McLaurin J, Golomb R, Jurewicz A, Antel J, Fraser P . Inositol stereoisomers stabilize an oligomeric aggregate of Alzheimer amyloid beta peptide and inhibit abeta -induced toxicity. J Biol Chem. 2000; 275(24):18495-502. DOI: 10.1074/jbc.M906994199. View

11.

Pinter J, Brown W, Eliez S, Schmitt J, Capone G, Reiss A . Amygdala and hippocampal volumes in children with Down syndrome: a high-resolution MRI study. Neurology. 2001; 56(7):972-4. DOI: 10.1212/wnl.56.7.972. View

12.

Sano M, Aisen P, Andrews H, Tsai W, Lai F, Dalton A . Vitamin E in aging persons with Down syndrome: A randomized, placebo-controlled clinical trial. Neurology. 2016; 86(22):2071-6. PMC: 4891209. DOI: 10.1212/WNL.0000000000002714. View

13.

Mohan M, Bennett C, Carpenter P . Galantamine for dementia in people with Down syndrome. Cochrane Database Syst Rev. 2009; (1):CD007656. PMC: 7197502. DOI: 10.1002/14651858.CD007656. View

14.

Mohan M, Bennett C, Carpenter P . Memantine for dementia in people with Down syndrome. Cochrane Database Syst Rev. 2009; (1):CD007657. PMC: 7197456. DOI: 10.1002/14651858.CD007657. View

15.

Shinno H, Inagaki T, Miyaoka T, Okazaki S, Kawamukai T, Utani E . A decrease in N-acetylaspartate and an increase in myoinositol in the anterior cingulate gyrus are associated with behavioral and psychological symptoms in Alzheimer's disease. J Neurol Sci. 2007; 260(1-2):132-8. DOI: 10.1016/j.jns.2007.04.017. View

16.

Lloyd A, Brett D, Wesnes K . Coherence training in children with attention-deficit hyperactivity disorder: cognitive functions and behavioral changes. Altern Ther Health Med. 2010; 16(4):34-42. View

17.

Berry G, Mallee J, Kwon H, Rim J, Mulla W, Muenke M . The human osmoregulatory Na+/myo-inositol cotransporter gene (SLC5A3): molecular cloning and localization to chromosome 21. Genomics. 1995; 25(2):507-13. DOI: 10.1016/0888-7543(95)80052-n. View

18.

Rafii M, Wishnek H, Brewer J, Donohue M, Ness S, Mobley W . The down syndrome biomarker initiative (DSBI) pilot: proof of concept for deep phenotyping of Alzheimer's disease biomarkers in down syndrome. Front Behav Neurosci. 2015; 9:239. PMC: 4568340. DOI: 10.3389/fnbeh.2015.00239. View

19.

Wisniewski K, Wisniewski H, Wen G . Occurrence of neuropathological changes and dementia of Alzheimer's disease in Down's syndrome. Ann Neurol. 1985; 17(3):278-82. DOI: 10.1002/ana.410170310. View

20.

Salloway S, Sperling R, Keren R, Porsteinsson A, van Dyck C, Tariot P . A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease. Neurology. 2011; 77(13):1253-62. PMC: 3179648. DOI: 10.1212/WNL.0b013e3182309fa5. View